Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL378363 | 0.91 | SRC (0.50) | SRCHTR1AALDH1A1KDM4EKMT2A | |
| SCHEMBL145729 | 0.89 | SRC (0.49) | SRCHTR1AALDH1A1KDM4EKMT2A | |
| SCHEMBL5351709 | 0.88 | SRC (0.53) | SRCALDH1A1KDM4EKMT2AMEN1 | |
| SCHEMBL8612271 | 0.85 | SRC (0.50) | SRCALDH1A1KDM4EKMT2AMEN1 | |
| SCHEMBL347037 | 0.81 | SRC (0.51) | SRCALDH1A1KMT2AMEN1MAPK1 | |
| SCHEMBL5144244 | 0.81 | SRC (0.47) | SRCALDH1A1KDM4EKMT2AGAA | |
| SCHEMBL2651217 | 0.81 | SRC (0.47) | SRCALDH1A1KDM4EKMT2AMEN1 | |
| SCHEMBL7679676 | 0.80 | SRC (0.46) | SRCALDH1A1KDM4EKMT2AMEN1 | |
| SCHEMBL15331405 | 0.80 | SRC (0.46) | SRCALDH1A1KDM4EKMT2AMEN1 | |
| SCHEMBL2744232 | 0.79 | TUBB1 (0.54) | BRD4ALDH1A1KDM4EKMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115160752-B | Polylactic acid composite material for mulching film and application thereof | 山西生物质新材料产业研究院有限公司 | 2023-08-01 | — | — | CN | claimed |
| CN-115160752-A | Polylactic acid composite material for mulching film and application thereof | 山西生物质新材料产业研究院有限公司 | 2022-10-11 | — | — | CN | claimed |
| CN-108997226-B | Synthesis process of cardiovascular drug Apabetalone | 合肥学院 | 2020-10-02 | — | — | CN | claimed |
| CN-108218798-B | Preparation method of Apabetalone | 南方医科大学 | 2020-04-24 | — | — | CN | claimed |
| CN-121248417-B | Chain extender based on waste PET, polyurethane sponge and preparation method | 梦百合家居科技股份有限公司 | 2026-02-24 | — | — | CN | disclosed |
| CN-121248417-A | Chain extender based on waste PET, polyurethane sponge and preparation method | 梦百合家居科技股份有限公司 | 2026-01-02 | — | — | CN | disclosed |
| EP-2408454-B1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP (CA) | 2024-07-24 | — | — | EP | disclosed |
| CN-115710202-B | Preparation method and application of apataone key intermediate | 江西同和药业股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-115160752-B | Polylactic acid composite material for mulching film and application thereof | 山西生物质新材料产业研究院有限公司 | 2023-08-01 | — | — | CN | disclosed |
| CN-107252429-B | Novel anti-inflammatory agent | 雷斯韦洛吉克斯公司 | 2023-06-16 | — | — | CN | disclosed |
| CN-115710202-A | Preparation method and application of apatazone key intermediate | 江西同和药业股份有限公司 | 2023-02-24 | — | — | CN | disclosed |
| CN-115160752-A | Polylactic acid composite material for mulching film and application thereof | 山西生物质新材料产业研究院有限公司 | 2022-10-11 | — | — | CN | disclosed |
| WO-2010079431-A2 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE | RESVERLOGIX CORP. (CA) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010079431-A2 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE | RESVERLOGIX CORP. (CA) | 2010-07-15 | — | — | WO | disclosed |
| US-20100004448-A1 | METHODS OF PREPARING QUINAZOLINONE DERIVATIVES | RESVERLOGIX CORP. (CA) | 2010-01-07 | — | — | US | disclosed |
| US-20100004448-A1 | METHODS OF PREPARING QUINAZOLINONE DERIVATIVES | RESVERLOGIX CORP. (CA) | 2010-01-07 | — | — | US | disclosed |
| WO-2009158404-A1 | METHODS OF PREPARING QUINAZOLINONE DERIVATIVES | RESVERLOGIX CORP. (CA) | 2009-12-30 | — | — | WO | disclosed |
| EP-2118074-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2009-11-18 | — | — | EP | disclosed |
| US-20080188467-A1 | To regulate the expression of apolipoprotein A-I; atherosclerosis; improved pharmacological properties; 3-(4-hydroxy-3,5-dimethylphenyl)-6,8-dimethoxyisoquinolin-1(2H)-one; to reduce cholesterol levels; agonists | HEPALINK (HONG KONG) LIMITED (HK) | 2008-08-07 | — | — | US | disclosed |
| WO-2008092231-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004448-A1 | METHODS OF PREPARING QUINAZOLINONE DERIVATIVES | APOB, APOL1, LDLR | SRC 4393/4885HTR1A 2018/4885BRD4 1306/4885 |
| US-20080188467-A1 | To regulate the expression of apolipoprotein A-I; atherosclerosis; improved pharmacological properties; 3-(4-hydroxy-3,5-dimethylphenyl)-6,8-dimethoxyisoquinolin-1(2H)-one; to reduce cholesterol levels; agonists | APOB, LDLR, APOL1 | SRC 3625/4885HTR1A 438/4885BRD4 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.